MCID: ANT024
MIFTS: 61

Anthrax Disease

Categories: Infectious diseases, Rare diseases

Aliases & Classifications for Anthrax Disease

MalaCards integrated aliases for Anthrax Disease:

Name: Anthrax Disease 12 15 74
Anthrax 77 54 56 44 3 45
Ragpicker's Disease 54 74
Wool Sorter's Disease 54
Cutaneous Anthrax 74
Malignant Pustule 54
Malignant Edema 54
Siberian Plague 54
Gas Gangrene 74
Black Baine 54

Classifications:



External Ids:

Disease Ontology 12 DOID:7427
ICD9CM 36 022 022.9
MeSH 45 D000881
NCIt 51 C84565
SNOMED-CT 69 17540007
ICD10 34 A22 A22.9

Summaries for Anthrax Disease

NIH Rare Diseases : 54 Anthrax is an infection caused by the bacterium Bacillus anthracis. The severity of the condition, the associated signs and symptoms and the prognosis vary depending on which part of the body is involved (see below). Antibiotics can be used to treat all forms of anthrax. Antitoxin medications may also be used to treat some forms of the condition. Cutaneous (skin) anthrax occurs when the infection enters the body through a cut or sore on the skin. It is the most common type of anthrax and generally the least serious. Affected people may experience a group of small, itchy bumps; swelling around a sore; and/or a painless ulcer with a black center. These skin abnormalities are generally found on the face, neck, arms, or hands. With appropriate treatment, cutaneous anthrax is seldom fatal. Gastrointestinal anthrax is caused by eating undercooked meat from an infected animal. Signs and symptoms may include nausea, vomiting, abdominal pain, headache, loss of appetite, fever, and a sore throat. Pulmonary (lung) anthrax occurs when anthrax spores are inhaled. It is the most deadly form of the condition. Early signs include flu-like symptoms, shortness of breath, nausea, and coughing up blood. As the condition advances, affected people may develop high fever, difficulty breathing, shock, and meningitis. Even with treatment, pulmonary anthrax may be fatal.Injection anthrax is spread by injecting illegal drugs. Signs and symptoms of this form of anthrax include redness and swelling at the sight of the infection. The condition may progress to shock, multiple organ failure and meningitis.

MalaCards based summary : Anthrax Disease, also known as anthrax, is related to inhalation anthrax and cutaneous anthrax, and has symptoms including skin ulcer, nausea and poor appetite. An important gene associated with Anthrax Disease is ANTXR1 (ANTXR Cell Adhesion Molecule 1), and among its related pathways/superpathways are HIV Life Cycle and Toll-like Receptor Signaling Pathway. The drugs Histamine and Diphenhydramine have been mentioned in the context of this disorder. Affiliated tissues include lung, skin and testes, and related phenotypes are cardiovascular system and cellular

Disease Ontology : 12 A primary bacterial infectious disease that results in infection located in skin, located in lung lymph nodes or located in gastrointestinal tract, has material basis in Bacillus anthracis, transmitted by contact with infected animals or animal products, transmitted by airborne spores or transmitted by ingestion of undercooked meat from infected animals and has symptom skin ulcer, has symptom nausea, has symptom poor appetite, has symptom bloody diarrhea, has symptom fever or has symptom shortness of breath.

MedlinePlus : 44 Anthrax is a disease caused by Bacillus anthracis, a germ that lives in soil. Many people know about it from the 2001 bioterror attacks. In the attacks, someone purposely spread anthrax through the U.S. mail. This killed five people and made 22 sick. Anthrax is rare. It affects animals such as cattle, sheep, and goats more often than people. People can get anthrax from contact with infected animals, wool, meat, or hides. It can cause three forms of disease in people. They are Cutaneous, which affects the skin. People with cuts or open sores can get it if they touch the bacteria. Inhalation, which affects the lungs. You can get this if you breathe in spores of the bacteria. Gastrointestinal, which affects the digestive system. You can get it by eating infected meat. Antibiotics often cure anthrax if it is diagnosed early. But many people don't know they have anthrax until it is too late to treat. A vaccine to prevent anthrax is available for people in the military and others at high risk. NIH: National Institute of Allergy and Infectious Diseases

CDC : 3 SymptomsWho is at Risk of ExposureTypes of Anthrax

Wikipedia : 77 Anthrax is an infection caused by the bacterium Bacillus anthracis. It can occur in four forms: skin,... more...

Related Diseases for Anthrax Disease

Diseases related to Anthrax Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 117)
# Related Disease Score Top Affiliating Genes
1 inhalation anthrax 33.0 ANTXR1 ANTXR2
2 cutaneous anthrax 31.6 CASP1 PRDX1
3 oropharyngeal anthrax 12.5
4 gapo syndrome 11.1
5 gastrointestinal anthrax 11.1
6 meningitis 10.5
7 plague 10.4
8 variola major 10.4
9 smallpox 10.4
10 influenza 10.3
11 cholera 10.3
12 meningoencephalitis 10.2
13 pancreatic ductal adenocarcinoma 10.2
14 tularemia 10.2
15 intraocular pressure quantitative trait locus 10.2
16 hepatitis 10.2
17 hepatitis b 10.1
18 rabies 10.1
19 body mass index quantitative trait locus 1 10.1
20 pertussis 10.1
21 tetanus 10.1
22 diphtheria 10.1
23 melanoma 10.1
24 cellulitis 10.1
25 pneumonia 10.1
26 spondyloarthropathy 1 10.0
27 foodborne botulism 10.0
28 brucellosis 10.0
29 optic neuritis 10.0
30 neuritis 10.0
31 spondylitis 10.0
32 vasculitis 10.0
33 encephalitis 10.0
34 cerebral amyloid angiopathy, itm2b-related, 1 9.9 FURIN PCSK6
35 rheumatoid arthritis 9.9
36 tetralogy of fallot 9.9
37 hyaline fibromatosis syndrome 9.9
38 anxiety 9.9
39 arthritis 9.9
40 leukemia 9.9
41 cicatricial ectropion 9.9
42 glanders 9.9
43 facial paralysis 9.9
44 urticaria 9.9
45 ectropion 9.9
46 mouth disease 9.9
47 compartment syndrome 9.9
48 venezuelan equine encephalitis 9.9
49 lymphocytic vasculitis 9.9
50 hepatocellular carcinoma 9.8

Graphical network of the top 20 diseases related to Anthrax Disease:



Diseases related to Anthrax Disease

Symptoms & Phenotypes for Anthrax Disease

Symptoms:

12
  • skin ulcer
  • nausea
  • poor appetite
  • bloody diarrhea
  • fever or has_symptom shortness of breath

UMLS symptoms related to Anthrax Disease:


fever, pruritus

MGI Mouse Phenotypes related to Anthrax Disease:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.01 ANTXR1 ANTXR2 CASP1 FURIN MAP2K1 MAP2K2
2 cellular MP:0005384 9.91 ANTXR1 ANTXR2 CASP1 MAP2K1 MAP2K2 MKKS
3 mortality/aging MP:0010768 9.81 ANTXR1 ANTXR2 CASP1 FURIN MAP2K1 MAP2K2
4 craniofacial MP:0005382 9.72 ANTXR1 MAP2K1 MAP2K2 MKKS PCSK6
5 digestive/alimentary MP:0005381 9.65 CASP1 FURIN MAP2K1 MAP2K2 PCSK6
6 neoplasm MP:0002006 9.43 ANTXR1 CASP1 MAP2K1 MAP2K2 PCSK6 PRDX1
7 reproductive system MP:0005389 9.1 ANTXR1 ANTXR2 CASP1 MAP2K1 MKKS PCSK6

Drugs & Therapeutics for Anthrax Disease

Drugs for Anthrax Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 57)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Histamine Approved, Investigational Phase 4,Phase 1 51-45-6 774
2
Diphenhydramine Approved, Investigational Phase 4 147-24-0, 58-73-1 3100
3
Promethazine Approved, Investigational Phase 4 60-87-7 4927
4 Immunologic Factors Phase 4,Phase 2,Phase 3,Phase 1
5 Vaccines Phase 4,Phase 3,Phase 2,Phase 1
6 Dermatologic Agents Phase 4
7 Central Nervous System Depressants Phase 4
8 Neurotransmitter Agents Phase 4
9
Histamine Phosphate Phase 4,Phase 1 51-74-1 65513
10 Gastrointestinal Agents Phase 4,Phase 2,Phase 1
11 Anesthetics Phase 4
12 Anesthetics, Local Phase 4
13 Histamine H1 Antagonists Phase 4
14 Immunoglobulins Phase 4,Phase 2,Phase 3,Phase 1
15 Histamine Antagonists Phase 4
16 Antipruritics Phase 4
17 Hypnotics and Sedatives Phase 4
18 Antiemetics Phase 4
19 Anti-Allergic Agents Phase 4
20 Antibodies, Monoclonal Phase 4,Phase 2,Phase 3,Phase 1
21 Antibodies Phase 4,Phase 2,Phase 3,Phase 1
22 Autonomic Agents Phase 4
23 Peripheral Nervous System Agents Phase 4
24 Antitoxins Phase 4,Phase 1,Phase 2
25 Antibodies, Blocking Phase 4
26
Sodium Citrate Approved, Investigational Phase 2, Phase 3,Phase 1 68-04-2
27
Glycine Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 56-40-6 750
28
Citric Acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3,Phase 1 77-92-9 311
29 Citrate Phase 2, Phase 3,Phase 1
30
Glyburide Approved Phase 2,Phase 1 10238-21-8 3488
31
Aluminum hydroxide Approved, Investigational Phase 2,Phase 1 21645-51-2
32
Ciprofloxacin Approved, Investigational Phase 2,Phase 1 85721-33-1 2764
33
Imidacloprid Vet_approved Phase 2,Phase 1 105827-78-9 86418
34 Hypoglycemic Agents Phase 2,Phase 1
35 Antacids Phase 2,Phase 1
36 Anti-Ulcer Agents Phase 2,Phase 1
37 Adjuvants, Immunologic Phase 2,Phase 1
38 Immunoglobulins, Intravenous Phase 1, Phase 2
39 Immunoglobulin G Phase 1, Phase 2
40 gamma-Globulins Phase 1, Phase 2
41 Rho(D) Immune Globulin Phase 1, Phase 2
42 Topoisomerase Inhibitors Phase 2,Phase 1
43 Anti-Bacterial Agents Phase 2,Phase 1
44 Cytochrome P-450 CYP1A2 Inhibitors Phase 2,Phase 1
45 Cytochrome P-450 Enzyme Inhibitors Phase 2,Phase 1
46 Anti-Infective Agents Phase 2,Phase 1
47 Pharmaceutical Solutions Phase 2,Phase 1
48
Mannitol Approved, Investigational Phase 1 69-65-8 6251 453
49
Edetic Acid Approved, Vet_approved Phase 1 60-00-4, 62-33-9 6049
50
Pentetic acid Approved Phase 1 67-43-6

Interventional clinical trials:

(show top 50) (show all 53)
# Name Status NCT ID Phase Drugs
1 CDC Anthrax Vaccine Clinical Trial Completed NCT00119067 Phase 4
2 Effect of Raxibacumab on Immunogenicity of Anthrax Vaccine Adsorbed Completed NCT02339155 Phase 4 Diphenhydramine
3 Assessment of the Immunogenicity and Safety of a Dose-Sparing BioThrax® AVA Schedule Completed NCT01641991 Phase 4
4 An Open Label Field Study of Anthim (Obiltoxaximab) in Subjects Exposed to B. Anthracis Not yet recruiting NCT03088111 Phase 4
5 Clinical Benefit, Safety and PK of Raxibacumab in Subjects Exposed to Bacillus Anthracis Not yet recruiting NCT02177721 Phase 4
6 Immunogenicity and Safety Study of a Three-Dose BioThrax® Regimen for Post-Exposure Prophylaxis in Healthy Adults Completed NCT01491607 Phase 3
7 An Open-label, Nonrandomized Study to Evaluate the Safety and Immunogenicity of Raxibacumab With Reinjection Completed NCT02016963 Phase 2, Phase 3
8 VELOCITY: An Anthrax Vaccine Clinical Study Recruiting NCT03877926 Phase 3
9 Glyburide Advantage in Malignant Edema and Stroke - Remedy Pharmaceuticals Unknown status NCT01794182 Phase 2 RP-1127 (Glyburide for Injection)
10 A Phase 2 Safety and Immunogenicity Study for an Anthrax Vaccine Using 3 Schedules and Two Dose Levels Completed NCT01770743 Phase 2
11 Safety, Tolerability and Immunogenicity of Recombinant Anthrax Vaccine Compared With Anthrax Vaccine Adsorbed Completed NCT00170469 Phase 2
12 Safety and Pharmacokinetics Study of Anthrax Immune Globulin Intravenous (AIGIV) Completed NCT00845650 Phase 1, Phase 2
13 Phase II Study of Range and Schedule of rPA Doses Completed NCT00170456 Phase 2
14 Ciprofloxacin BioThrax Co-Administration Study Completed NCT01753115 Phase 2 Ciprofloxacin
15 Trial of rPA-102 Vaccine in Healthy Adult Volunteers Completed NCT00100724 Phase 2
16 Glyburide Advantage in Malignant Edema and Stroke Pilot Completed NCT01268683 Phase 1, Phase 2 RP-1127 (Glyburide for injection)
17 BARDA Securing Anthrax Immunity For the Elderly Active, not recruiting NCT03518125 Phase 2 Sodium chloride injection USP, 0.9% (placebo)
18 A Study to Assess Dose-Response, Efficacy (Immunogenicity) and the Safety of GC1109 Suspended NCT01624532 Phase 2 Normal Saline
19 UMD rPA Regimen Trial in Adults Terminated NCT00133484 Phase 2
20 A Phase 1 Ascending Dose Study to Assess the Safety and Immunogenicity of Adenovirus Anthrax Vector Candidate Vaccines Completed NCT01979406 Phase 1
21 A New Anthrax Vaccine Administered by the Intramuscular (IM) Route in Healthy Adults Completed NCT00057525 Phase 1
22 Anthrax-rPA: Safety, Tolerability, Immunogenicity Completed NCT00063843 Phase 1
23 Anthrax Vaccine Clinical Trials Completed NCT00114621 Phase 1 Anthrax Vaccine
24 Safety and Pharmacokinetic Study of Anthrax Immune Globulin Derived From Human Serum Completed NCT00448253 Phase 1
25 Safety, Tolerability and Immunogenicity Study of AV7909 Anthrax Vaccine in Healthy Adults Completed NCT01263691 Phase 1 Control
26 A Study of Anthrax Vaccines Px563L and RPA563 in Healthy Adult Subjects Completed NCT02655549 Phase 1
27 Trial to Evaluate the Safety and Immunogenicity of an Anthrax Recombinant Protective Antigen Vaccine Completed NCT00103467 Phase 1
28 PA83-FhCMB Plant-Derived Recombinant Protective Antigen (rPA) Anthrax Vaccine Completed NCT02239172 Phase 1
29 Efficacy and Safety of Anthrax Vaccine, GC1109 Completed NCT01867957 Phase 1
30 Monoclonal Antibody for Treatment of Inhalation Anthrax Completed NCT00138411 Phase 1 Ciprofloxacin 500 mg;ETI-204 (Anthim)
31 Dose Escalation Study of Valortim® (MDX-1303) Administered Intravenously (IV) in Healthy, Normal Subjects Completed NCT01265745 Phase 1 Normal Saline for Injection
32 Safety, Tolerability and PK of Repeat Administration of Intravenous ETI-204 in Adult Volunteers Completed NCT01932242 Phase 1
33 Safety, Tolerability, and PK of a Single Intravenous Dose of ETI-204 in Adult Volunteers Completed NCT01929226 Phase 1
34 Single Dose, Weight-Based, Dose-Escalation Study With Intravenous ETI-204 in Adult Volunteers Completed NCT01453907 Phase 1 ETI-204, "Anthim";placebo
35 Safety and Pharmacokinetics Study of Human Monoclonal Antibody (AVP-21D9) Completed NCT01202695 Phase 1 AVP-21D9;Placebo
36 Safety, Tolerability and PK of Intravenous (IV) ETI-204 Alone and in Presence of Ciprofloxacin in Adult Volunteers Completed NCT01952444 Phase 1 Ciprofloxacin
37 Intramuscular Dose-Escalation Study With ETI-204 in Adult Volunteers Completed NCT01932437 Phase 1
38 Study of Valortim® (MDX-1303) and Its Selected Formulation Components Percutaneous Use Completed NCT01204866 Phase 1 Valortim and Selected Components
39 A Phase I Study of Safety and Immunogenicity of the WRAIR HIV-1 Vaccine Completed NCT00412477 Phase 1
40 NasoShield Study of Safety and Immunogenicity Active, not recruiting NCT03352466 Phase 1
41 Ph1 Study of Valortim and Ciprofloxacin in Humans Suspended NCT00964561 Phase 1 Ciprofloxacin and Valortim;Placebo Antibiotic and Valortim
42 Ph1 Study of Valortim and Doxycycline in Humans Terminated NCT00964834 Phase 1 Doxycycline and Valortim;Placebo Antibiotic and Valortim;Placebo Antibiotic and Placebo Valortim
43 Plasmapheresis of Anthrax-Vaccinated Subjects for Production of Anthrax Immune Globulin Completed NCT00031291 Anthrax Immune Globulin
44 Febrile Whole Blood Specimen Collection and Testing Completed NCT03498027
45 VHA Clinicians and Bioterror Events: Interactive Web-based Learning Completed NCT00123396 Not Applicable
46 Special Drug Use Investigation of Ciproxan Injection in Pediatrics Completed NCT02555059 Cipro (Ciprofloxacin, BAYQ3939)
47 Ciprofloxacin Special Drug Use Investigation - To Investigate the Safety and Efficacy in Patients With Ciprofloxacin iv Administration Without Dilution Completed NCT01690559 Cipro (Ciprofloxacin, BAYQ3939)
48 Assessment of the Safety and Efficacy of Ciproxan-I.V. in Daily Clinical Practice - Analysis Results From a Post-marketing Surveillance Completed NCT01670435 Ciprofloxacin (BAYQ3939)
49 Natural History of Anthrax: a Study of Primary Infected, Recovered, and Exposed Individuals (SPoRE); and Evaluation of AVA-Vaccinated Recipients Recruiting NCT00050310
50 Admission and Management of Occupational or Other Exposures to Biodefense/Bioterrorism Agents or to Epidemic/Emerging Infectious Diseases Recruiting NCT01200953

Search NIH Clinical Center for Anthrax Disease

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cochrane evidence based reviews: anthrax

Genetic Tests for Anthrax Disease

Anatomical Context for Anthrax Disease

MalaCards organs/tissues related to Anthrax Disease:

42
Lung, Skin, Testes, Lymph Node, Endothelial, T Cells, Neutrophil

The Foundational Model of Anatomy Ontology organs/tissues related to Anthrax Disease:

20
Skin, Lung Lymph Nodes Or

Publications for Anthrax Disease

Articles related to Anthrax Disease:

(show top 50) (show all 2989)
# Title Authors Year
1
An Optimal Control Model to Reduce and Eradicate Anthrax Disease in Herbivorous Animals. ( 30357598 )
2019
2
An ELISA using a recombinant chimera of protective antigen and lethal factor for serodiagnosis of cutaneous anthrax in India. ( 30635155 )
2019
3
Cutaneous Anthrax Outbreak in the Trakya Region of Turkey ( 30701847 )
2019
4
Gastrointestinal and cutaneous anthrax: Case series. ( 31073544 )
2019
5
Targeting Anthrax Toxin Receptor 2 Ameliorates Endometriosis Progression. ( 30809297 )
2019
6
Zeptomole per milliliter detection and quantification of edema factor in plasma by LC-MS/MS yields insights into toxemia and the progression of inhalation anthrax. ( 30911800 )
2019
7
Anthrax toxin requires ZDHHC5-mediated palmitoylation of its surface-processing host enzymes. ( 30610172 )
2019
8
Europium functionalized silicon quantum dots nanomaterials for ratiometric fluorescence detection of Bacillus anthrax biomarker. ( 30616167 )
2019
9
A new triple chimeric protein as a high immunogenic antigen against anthrax toxins: theoretical and experimental analyses. ( 30621469 )
2019
10
Development of a novel multiepitope chimeric vaccine against anthrax. ( 30671633 )
2019
11
Single dose of DPX-rPA, an enhanced-delivery anthrax vaccine formulation, protects against a lethal Bacillusanthracis spore inhalation challenge. ( 30774997 )
2019
12
Detection of Bacillus anthracis in Animal Tissues using InBios Active Anthrax Detect Rapid Test Lateral Flow Immunoassay. ( 30776143 )
2019
13
Accurate and selective quantification of anthrax protective antigen in plasma by immunocapture and isotope dilution mass spectrometry. ( 30810119 )
2019
14
The elephant-livestock interface modulates anthrax suitability in India. ( 30862290 )
2019
15
Development and Performance of a Checklist for Initial Triage After an Anthrax Mass Exposure Event. ( 30884525 )
2019
16
Risk mapping and eco-anthropogenic assessment of anthrax in the upper Zambezi basin. ( 30920176 )
2019
17
Bismaleimide cross-linked anthrax toxin forms functional octamers with high-specificity in tumor targeting. ( 30942916 )
2019
18
Multiporous Terbium Phosphonate Coordination Polymer Microspheres as Fluorescent Probes for Trace Anthrax Biomarker Detection. ( 30951283 )
2019
19
Tumor imaging using radiolabelled matrix metalloproteinase-activated anthrax proteins. ( 30954944 )
2019
20
Anthrax Epizootic in Wildlife, Bwabwata National Park, Namibia, 2017. ( 31002072 )
2019
21
Risk factors associated with the occurrence of anthrax outbreaks in livestock in the country of Georgia: A case-control investigation 2013-2015. ( 31048838 )
2019
22
The N-end rule ubiquitin ligase UBR2 mediates NLRP1B inflammasome activation by anthrax lethal toxin. ( 31061172 )
2019
23
Heme Catabolism in the Causative Agent of Anthrax. ( 31063630 )
2019
24
A highly selective lanthanide-containing probe for ratiometric luminescence detection of an anthrax biomarker. ( 31065665 )
2019
25
The global distribution of Bacillus anthracis and associated anthrax risk to humans, livestock and wildlife. ( 31086311 )
2019
26
Comparison of spatiotemporal patterns of historic natural Anthrax outbreaks in Minnesota and Kazakhstan. ( 31100100 )
2019
27
Anthrax biomarker: An ultrasensitive fluorescent ratiometry of dipicolinic acid by using terbium(III)-modified carbon dots. ( 30262082 )
2019
28
Constructing and transient expression of a gene cassette containing edible vaccine elements and shigellosis, anthrax and cholera recombinant antigens in tomato. ( 30244396 )
2018
29
Quantitative Prediction of Multivalent Ligand-Receptor Binding Affinities for Influenza, Cholera, and Anthrax Inhibition. ( 29474056 )
2018
30
Two cases of human cutaneous anthrax with massive tissue damage, severe edema, and slight injury to the liver. ( 29231245 )
2018
31
Rates and risk factors for human cutaneous anthrax in the country of Georgia: National surveillance data, 2008-2015. ( 29415029 )
2018
32
Correction: Rates and risk factors for human cutaneous anthrax in the country of Georgia: National surveillance data, 2008-2015. ( 29718987 )
2018
33
Risk factors for human cutaneous anthrax outbreaks in the hotspot districts of Northern Tanzania: an unmatched case-control study. ( 30839712 )
2018
34
Obiltoxaximab (Anthim) for inhalation anthrax. ( 30383733 )
2018
35
Treating Anthrax-Induced Meningitis in Rabbits. ( 29661872 )
2018
36
A Bacteriophage T4 Nanoparticle-Based Dual Vaccine against Anthrax and Plague. ( 30327445 )
2018
37
Simultaneous Immunodetection of Anthrax, Plague, and Tularemia from Blood Cultures by Use of Multiplexed Suspension Arrays. ( 29386263 )
2018
38
Single vector platform vaccine protects against lethal respiratory challenge with Tier 1 select agents of anthrax, plague, and tularemia. ( 29725025 )
2018
39
A biallelic ANTXR1 variant expands the anthrax toxin receptor associated phenotype to tooth agenesis. ( 29436111 )
2018
40
Validated MALDI-TOF-MS method for anthrax lethal factor provides early diagnosis and evaluation of therapeutics. ( 29224733 )
2018
41
Evaluation of in vitro antimicrobial susceptibility of Bacillus anthracis strains isolated during anthrax outbreaks in Italy from 1984 to 2017. ( 30541185 )
2018
42
Hydrogen peroxide-assisted ultrasonic synthesis of BCNO QDs for the anthrax biomarker detection. ( 30576100 )
2018
43
Identification of Therapeutically Active Molecules against Anthrax through Structure and Ligand based Drug Design. ( 30582475 )
2018
44
Investigation of anthrax in an endemic region in Kenya: a mixed methods approach. ( 30858916 )
2018
45
DUST-BATHING BEHAVIORS OF AFRICAN HERBIVORES AND THE POTENTIAL RISK OF INHALATIONAL ANTHRAX. ( 29053428 )
2018
46
Ratiometric fluorescence detection of an anthrax biomarker with Eu3+-chelated chitosan biopolymers. ( 29103500 )
2018
47
Small molecule inhibitors of anthrax edema factor. ( 29198864 )
2018
48
Galactosylation of the Secondary Cell Wall Polysaccharide of Bacillus anthracis and Its Contribution to Anthrax Pathogenesis. ( 29229702 )
2018
49
Anthrax outbreaks in the humans - livestock and wildlife interface areas of Northern Tanzania: a retrospective record review 2006-2016. ( 29304765 )
2018
50
Ecological suitability modeling for anthrax in the Kruger National Park, South Africa. ( 29377918 )
2018

Variations for Anthrax Disease

Expression for Anthrax Disease

Search GEO for disease gene expression data for Anthrax Disease.

Pathways for Anthrax Disease

Pathways related to Anthrax Disease according to GeneCards Suite gene sharing:

(show all 27)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.36 ANTXR1 ANTXR2 FURIN MAP2K1 MAP2K2 PRDX1
2
Show member pathways
12.59 ANTXR1 ANTXR2 CASP1 MAP2K1 MAP2K2
3
Show member pathways
12.29 CASP1 MAP2K1 MAP2K2
4
Show member pathways
12.01 CASP1 MAP2K1 MAP2K2
5
Show member pathways
11.91 CASP1 MAP2K1 MAP2K2
6
Show member pathways
11.59 CASP1 MAP2K1 MAP2K2
7 11.35 MAP2K1 MAP2K2
8
Show member pathways
11.32 FURIN PCSK6
9 11.29 MAP2K1 MAP2K2
10
Show member pathways
11.27 MAP2K1 MAP2K2
11 11.25 MAP2K1 MAP2K2
12
Show member pathways
11.25 ANTXR1 ANTXR2 FURIN MAP2K1 MAP2K2
13 11.24 MAP2K1 MAP2K2
14 11.23 MAP2K1 MAP2K2
15
Show member pathways
11.21 MAP2K1 MAP2K2
16 11.21 MAP2K1 MAP2K2
17 11.11 MAP2K1 MAP2K2
18 11.09 MAP2K1 MAP2K2
19 11.07 MAP2K1 MAP2K2
20 10.98 MAP2K1 MAP2K2
21 10.8 MAP2K1 MAP2K2
22 10.76 MAP2K1 MAP2K2
23 10.71 MAP2K1 MAP2K2
24 10.66 MAP2K1 MAP2K2
25 10.62 MAP2K1 MAP2K2
26 10.36 ANTXR1 ANTXR2 CASP1 MAP2K1 MAP2K2
27
Show member pathways
9.85 FURIN PCSK6

GO Terms for Anthrax Disease

Cellular components related to Anthrax Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 endoplasmic reticulum GO:0005783 9.35 ANTXR2 FURIN MAP2K1 MAP2K2 PCSK6
2 endosome membrane GO:0010008 9.33 ANTXR1 ANTXR2 FURIN
3 cell surface GO:0009986 8.92 ANTXR1 ANTXR2 FURIN PCSK6

Biological processes related to Anthrax Disease according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of gene expression GO:0010629 9.7 MAP2K1 MAP2K2 MKKS
2 stress-activated protein kinase signaling cascade GO:0031098 9.55 MAP2K1 MAP2K2
3 positive regulation of protein serine/threonine kinase activity GO:0071902 9.54 MAP2K1 MAP2K2
4 toxin transport GO:1901998 9.51 ANTXR1 ANTXR2
5 ERK1 and ERK2 cascade GO:0070371 9.49 MAP2K1 MAP2K2
6 peptide hormone processing GO:0016486 9.48 FURIN PCSK6
7 face development GO:0060324 9.46 MAP2K1 MKKS
8 reproductive process GO:0022414 9.43 ANTXR1 ANTXR2
9 secretion by cell GO:0032940 9.4 FURIN PCSK6
10 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.37 MAP2K1 MAP2K2
11 regulation of lipoprotein lipase activity GO:0051004 9.32 FURIN PCSK6
12 regulation of early endosome to late endosome transport GO:2000641 9.26 MAP2K1 MAP2K2
13 regulation of Golgi inheritance GO:0090170 9.16 MAP2K1 MAP2K2
14 nerve growth factor production GO:0032902 8.96 FURIN PCSK6
15 regulation of stress-activated MAPK cascade GO:0032872 8.8 MAP2K1 MAP2K2 PRDX1

Molecular functions related to Anthrax Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein serine/threonine kinase activator activity GO:0043539 9.32 MAP2K1 MAP2K2
2 protein serine/threonine/tyrosine kinase activity GO:0004712 9.26 MAP2K1 MAP2K2
3 MAP kinase kinase activity GO:0004708 9.16 MAP2K1 MAP2K2
4 endopeptidase activity GO:0004175 9.13 CASP1 FURIN PCSK6
5 nerve growth factor binding GO:0048406 8.62 FURIN PCSK6
6 protein binding GO:0005515 10.02 ANTXR1 ANTXR2 CASP1 FURIN MAP2K1 MAP2K2

Sources for Anthrax Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....